BioCentury
ARTICLE | Company News

Medicines Co., U.S. Department of Health and Human Services (HHS) infectious news

February 10, 2014 8:00 AM UTC

HHS's Biomedical Advanced Research and Development Agency awarded The Medicines Co. a contract worth up to $90 million to develop Carbavance for serious Gram-negative infections as well as melioidosis and glanders, which are caused by the bioterrorism agents Burkholderia pseudomallei and B. mallei, respectively. The Medicines Co. will receive $19.8 million initially, with the contract worth $90 million if extended to the full five years. ...